India, April 13 -- Allogene Therapeutics, Inc. (ALLO) shares jumped 48.90 percent, gaining $1.33 to $4.05 on Monday, after promising interim data from its ALPHA3 trial evaluating its CAR-T therapy cema-cel in lymphoma patients.
The stock is currently trading at $4.05 compared with its previous close of $2.72, after opening at $4.08 on the Nasdaq. Shares traded between $3.55 and $4.09 during the session, with volume surging to 34.94 million shares, well above the average daily volume of 5.83 million.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The company reported that 58.3 percent of patients treated with cema-cel achieved molecular residual disease clearance, with significant reductions in circul...